A Phase I, Open-Label, Sequential, Single-Dose Study to Assess the Absolute Bioavailability and Pharmacokinetics of TMC435 Administered as Single Oral Doses of 50 mg and 150 mg and an Intravenous Microdose of 100 mcg [3H]-TMC435 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2012
At a glance
- Drugs Simeprevir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 07 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Nov 2012 New trial record